Leukocytosis, vascular disease, and adenine nucleotide metabolism.
Explore the source record for details and available documents.
Adenosine Diphosphate↗
Biomedical subjects
Bethan Myers
Publications and source records attributed to Bethan Myers.
Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
We evaluated the combination of thalidomide, pulsed dexamethasone and weekly cyclophosphamide (CTD) for the treatment of patients with newly diagnosed, relapsed or VAD-refractory multiple myeloma. We found that this combination was highly effective in inducing responses in all treatment groups with an overall response rate of 83.8%. CTD was well tolerated and did not impair stem cell mobilization.
Antineoplastic Combined Chemotherapy Protocols↗
Comment on systemic mastocytosis study.
Explore the source record for details and available documents.
Adult↗
Skin, bone marrow and magnetic resonance imaging appearances in systemic mastocytosis.
Explore the source record for details and available documents.
Adult↗
The place of beta 2 glycoprotein 1 in the assessment of antiphospholipid syndrome.
beta 2 glycoprotein 1 (beta2GP1) is a phospholipid-binding protein implicated in the development of antiphospholipid antibodies, associated with thromboembolic complications and fetal morbidity and death, and is thought to corrrelate better than anticardiolipin (aCL) assays. We analysed the role of beta2GP1 in assessing 86 patients being investigated for antiphospholipid syndrome. Thirty-nine patients had 3 tests: [lupus anticoagulant (LA), aCL and beta2GP1], and a further 46 had aCL and beta2GP1. Sixty-one patients had completely negative tests. Five patients had beta2GP1 as the only positive result. 80% of this group had recurrent miscarriage suggesting that beta2GP1 may be an useful adjunct to aCL and LA testing in patients with a significant obstetric history.
Abortion, Habitual↗
Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction.
We describe a case where danaparoid was used prophylactically in a high-risk twin pregnancy following the development of heparin-allergy while on prophylactic dalteparin. Danaparoid was substituted for dalteparin at 20 weeks of pregnancy following the development of a severe skin reaction while on the low molecular weight heparin. Although there was no significant fall in platelet count, an aggregation assay for heparin-induced thrombocytopaenia was positive. The skin lesions rapidly resolved following the change to subcutaneous danaparoid. Delivery was by emergency caesarian section at 35 weeks under a general anaesthetic, as a dose of danaparoid had been given 6 h prior to delivery. A sample of breast milk showed no anti-activated factor X activity. Danaparoid was continued post-delivery until the patient was fully warfarinized. To our knowledge, there are no previous reports of the use of danaparoid in this setting.
Adult↗